Optimists share similar brain patterns when thinking about the future, scans show
Now researchers have found that people with an upbeat outlook show similar patterns of brain activity when they mull over future scenarios.
'Optimists seem to use a shared neural framework for organising thoughts about the future, which likely reflects a similar style of mental processing rather than identical ideas,' said Kuniaki Yanagisawa, first author of the research from Kobe University in Japan.
He said the results could shed light on previous findings that showed optimists tended to be more socially successful.
'What this [new study] tells us is that the foundation of their social success might be this shared reality,' he added. 'It's not just about having a positive attitude; it's that their brains are literally on the same wavelength, which may allow for a deeper, more intuitive kind of connection.'
In the Proceedings of the National Academy of Sciences, the researchers said they asked 87 participants to complete a questionnaire to reveal how optimistic they were.
Each participant also underwent an MRI brain scan, during which they were asked to imagine various different possible future life events, some of which were positive – such as taking an 'epic trip around the world' – while others were neutral or negative, such as being fired. A subset of the participants were asked to imagine scenarios related to death.
The team found participants who were more optimistic showed greater similarities in the patterns of their brain activity in a region involved in future-oriented thinking, called the medial prefrontal cortex (MPFC)
Yanagisawa said one possibility was that the more diverse brain activity among pessimists reflected a more varied set of concerns when thinking about negative scenarios.
However, he said another possibility was that optimists viewed their futures within a shared framework of socially accepted goals which pessimists might feel disconnected from for personal reasons, meaning they each had a different way of thinking about the future.
The researchers said the results had parallels with the first line of Leo Tolstoy's novel Anna Karenina: 'Happy families are all alike; every unhappy family is unhappy in its own way.'
'On the basis of this principle, we propose that optimistic individuals are all alike, but each less optimistic individual imagines the future in their own way,' the team wrote.
The researchers also found patterns of brain activity in the MPFC showed clearer differences for positive and negative future events in optimists.
'This suggests that optimists not only 'think alike' in a structural sense, but they also process emotional information about the future differently with a greater ability to separate what's good from what's bad, which may help them stay resilient,' said Yanagisawa.
He said previous work had associated this kind of clearer separation with a more abstract, psychologically distant way of thinking about negative events.
'We're not saying that optimists have identical thoughts about the future, or that they imagine the exact same scenarios,' said Yanadisawa. 'Rather, what we found is that their brains represent future events in a similar way, especially in how they distinguish between positive and negative possibilities. So while we wouldn't say they have the same thoughts, we can say that they appear to think in the same way – structurally.'
Prof Lisa Bortolotti of the University of Birmingham, in the UK, who was not involved in the work, said the study suggested optimists pictured future negative events in less vivid and concrete detail than positive ones, meaning such potential scenarios affected them less.
'These findings might suggest that optimism does not amount to a form of irrationality or reality distortion because it does not change how we see things out there but how those things impact us,' she added.
Bortolotti said assuming things won't go wrong brought no benefits if it left us unprepared for challenges, but noted that optimism worked when it motivated us to pursue goals.
'Picturing a positive outcome in detail as feasible and desirable makes us value it and work for it, ultimately making it more likely that we will achieve it,' she said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Telegraph
an hour ago
- Telegraph
Covid vaccines ‘saved far fewer lives than first thought'
Covid vaccines saved far fewer lives than first thought, a major new analysis has concluded, with researchers criticising 'aggressive mandates'. In 2024, the World Health Organisation (WHO) claimed that jabs prevented the deaths of 14.4 million globally in the first year alone, with some estimates putting the figure closer to 20 million. However, new modelling by Stanford University and Italian researchers suggests that while the vaccine did undoubtedly save lives, the true figure is 'substantially more conservative' and closer to 2.5 million worldwide over the course of the entire pandemic. The team estimated that nine of 10 prevented deaths were in the over-60s, with jabs saving just 299 youngsters aged under 20, and 1,808 people aged between 20 and 30 globally. Overall 5,400 people needed to be vaccinated to save one life but in the under-30s this figure rose to 100,000 jabs, the paper suggests. Researchers criticised 'aggressive mandates and the zealotry to vaccinate everyone at all cost', adding that the findings had implications for how future vaccine rollouts are handled. John Ioannidis, Professor of Medicine at Stanford University and the first author, said: 'I think early estimates were based on many parameters having values that are incompatible with our current understanding. 'In principle, targeting the populations who would get the vast majority of the benefit and letting alone those with questionable risk-benefit and cost-benefit makes a lot of sense. 'Aggressive mandates and the zealotry to vaccinate everyone at all cost were probably a bad idea.' Since 2021, more than 13 billion Covid-19 vaccine doses have been administered. But there have been mounting concerns that vaccines could be harmful for some people, particularly the young, and that the risk was not worth the benefit for a population at little risk from Covid. More than 17,500 Britons have applied to the Government's vaccine damage payment scheme believing they or loved ones were injured by the jab. In June, manufacturers added warnings for myocarditis and pericarditis to Covid-19 messenger RNA (mRNA) vaccines' prescribing information. For the new study, experts used worldwide population data, alongside vaccine effectiveness and infection fatality rates, to estimate how many people died from a Covid infection before or after the periods of vaccination. The team believes earlier modelling may have used overly pessimistic infection fatality rates and overly optimistic vaccine effectiveness, while failing to consider how quickly protection waned. Based on fewer assumptions Earlier studies may also have underestimated how many people had already been unknowingly infected by the time they had the vaccine. Dr Angelo Maria Pezzullo, researcher in general and applied hygiene at the Catholic University of the Sacred Heart, in Milan, said: 'Before ours, several studies tried to estimate lives saved by vaccines with different models and in different periods or parts of the world, but this one is the most comprehensive because it is based on worldwide data. it also covers the omicron period. 'It also calculates the number of years of life that was saved, and it is based on fewer assumptions about the pandemic trend.' The team calculated that around 14.8 million life-years were saved, one life-year saved per 900 vaccine doses administered. Researchers concluded that although vaccines had a 'substantial benefit' on global mortality, it was 'mostly limited' to older people. The over-70s made up nearly 70 per cent of the lives saved, while the 60 to 70s accounted for a further 20 per cent. In contrast, under-20s made up just 0.01 per cent of lives saved and 20 to 30s were 0.07 per cent. Professor Stefania Boccia, of the Catholic University of the Sacred Heart, added: 'These estimates are substantially more conservative than previous calculations that focused mainly on the first year of vaccination, but clearly demonstrate an important overall benefit from Covid-19 vaccination over the period 2020-2024. 'Most of the benefits, in terms of lives and life-years saved, have been secured for a portion of the global population who is typically more fragile, the elderly.' Sir David Davis, the former Brexit secretary who fought against vaccine mandates, said: 'Frankly it's a good cautionary tale that if we have another pandemic we should be far more clinical about the risk-benefit ratio. 'We knew pretty quickly who the most susceptible groups were and we should have focused very strictly on them, rather than placing people who were at little risk in hazard's way. 'The level of aggression of trying to force people to become vaccinated and shutting down people who were raising concerns, the reasons for those concerns are all validated in this report.'
Daily Mail
2 hours ago
- Daily Mail
Doctors invent at-home test for condition that affects millions of Americans but goes undiagnosed for up to 10 YEARS
A first-of-its-kind at-home test can reveal whether a person suffers from endometriosis, a condition that leaves patients suffering from debilitating pain and without a diagnosis for up to a decade. Endometriosis is a condition that causes tissue similar to the lining of the uterus, or endometrium, to grow outside the uterus. It affects at least 11 percent of American women, more than 6.5 million. This tissue thickens and breaks down, but because it grows outside the uterus, there is no way for it to the leave body like typical lining does in blood during menstruation. It becomes trapped and leads to the formation of cysts. It often causes damage to the ovaries, fallopian tubes and the tissue lining the pelvis and can cause extreme menstrual pain, pain during sex, excessive bleeding, fatigue, diarrhea, constipation and fertility problems. Typically, it takes about a decade for doctors to diagnose endometriosis because of misdiagnosis, stigma and lack of access to proper healthcare - which can leave many women in excruciating pain for years. In many cases, doctors conduct a laparoscopy to diagnose endometriosis, which involves inserting a small camera in the body to find the extra tissue near the pelvis, taking a sample and testing it for confirmation. Once a diagnosis is made, potential treatments include birth control pills to stop the menstrual cycle or hormonal medication. As of now, there is no long-term treatment or cure for endometriosis. However, researchers at the Pennsylvania State University have now developed a new minimally invasive test patients can do themselves that can detect a biomarker for the disease in period blood and get a diagnosis - and start treatment - years earlier. Developed by Dr Dipanjan Pan, a Dorothy Foehr Huck & J. Lloyd Huck Chair Professor in Nanomedicine at the university, and his team, the at-home test offers up a diagnosis with nearly five times more accuracy than a laparoscopy in just 10 minutes. Dr Pan explained to Newsweek: 'This is the first time we have a proof of principle pregnancy-like test that shows one can collect menstrual blood and run it in the privacy of home and obtain the results in 10 minutes.' He noted that menstrual blood and tissue that is shed from the uterus each month is often overlooked as medical waste but could help with earlier and more accessible endometriosis detection. The team's prototype device can detect HMGB1 - a protein involved in endometriosis development and progression - in period blood with 500 percent more accuracy and confirm whether a person is suffering from the condition, he explained. To conduct the test, a sample of blood needs to be added to what looks like a Covid testing strip. If any HMGB1 proteins are present, they bind to the antibodies in the blood and when tested, turn two stripes dark - giving a positive result for endometriosis. In case of a negative result, only one stripe on the test darkens. Dr Pan told Newsweek: 'Currently, the only definitive [diagnostic] method is laparoscopic surgery [keyhole surgery, often invasive]. 'While menstrual blood is not yet a standard diagnostic tool for endometriosis, it's an active area of research with the potential to revolutionize how the condition is diagnosed and monitored in the future. 'With our technology, we are hoping to democratize women's health by providing a much-needed tool to track the onset or progression of this disease at the convenience and privacy of home. 'We anticipate that combining this technology with clinical symptoms will allow for early detection or diagnosis of endometriosis in adolescents and women.' Additionally, he also noted that the new test can help reduce the costs and time involved in scheduling and conducting a laparoscopy. He added: 'A recent study found that the average cost for a woman with endometriosis was around $30,000 per year. 'This huge financial burden can be reduced [as well as the shame and isolation from stigma] if an accurate at-home test becomes available. 'Our technology once developed, can reduce the time of diagnosis dramatically from years to minutes. 'Technologies are being developed that claim to be 'at-home' tests for endometriosis, but in fact they are developing ways to collect samples for laboratories to test.' Dr Pan also noted that with further testing and funding, he and his team intend to make the test accessible to people of all incomes. Furthermore, he also hopes to integrate the tests into period pads, making it possible to discreetly and conveniently monitor HMGB1 levels this way at home too. He said: 'It is our goal to [eventually] provide the kits directly to the public, at a reasonable price point, so women can do the test at home and share the results with their doctors, who will offer diagnoses and advice about next steps. 'We are looking at a couple of years of effort at this point. The team is actively looking for funding and partners to further develop the test. With funding, this timeline can be reduced in my opinion. '
Reuters
2 hours ago
- Reuters
Health Rounds: RSV can boost seniors' heart risks
July 24 (Reuters) - (This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here.) Older adults hospitalized for respiratory syncytial virus (RSV) face an elevated risk of developing heart failure and a dangerous heart rhythm problem, a Canadian study found. The risk for heart failure was seen even in individuals without a history of heart problems, researchers reported in the Journal of the American Geriatrics Society, opens new tab. The researchers reviewed data on more than 100,000 adults aged 65 and older hospitalized in Ontario between 2011 and 2020 for either RSV, influenza, urinary tract infection, or a fracture. The proportion of patients with a subsequent cardiovascular event was 18.5% after an RSV-related hospitalization, compared to 17.7%, 12.1% and 8.4% after hospitalizations for influenza, urinary tract infection, or fracture, respectively. In comparisons of patients who were closely matched according to demographics and risk factors, heart failure (10%–11%) was the most common outcome for RSV patients, occurring in 10% to 11%. Next most common was the heart rhythm disorder atrial fibrillation, occurring in 5% to 6% of RSV patients. The risk for those outcomes, as well as for heart attack, 'was at least two to three times higher in patients with a pre-existing cardiovascular condition compared to those without,' the researchers also said. 'Our findings reinforce the importance of RSV vaccination in older adults and suggest that monitoring for signs of heart disease following an RSV illness may be pragmatic,' study leader Chris Verschoor of Health Sciences North Research Institute in Sudbury, Ontario, said in a statement. Sending dye through the small intestine to look for blockages has been sparing a significant proportion of patients from needing to undergo surgery, a new study shows. The dye, Gastrografin from Bracco Diagnostics Inc., is administered to symptomatic patients before an X-ray or CT scan so that surgeons can see the location and severity of any so-called adhesive small bowel obstructions. Researchers reviewed nationwide data on more than 20,000 patients with suspected small bowel obstruction managed in two periods - 2012 to 2016, before Gastrografin was widely used for this purpose, and 2019 to 2023, when using Gastrografin to visualize intestinal blockages was a standard of care. They found nearly a 45% decrease in surgeries for small bowel obstruction in the Gastrografin era, from 13,257 to 7,333. Small bowel obstruction accounts for 15% of hospital admissions in the U.S., with about 20% of cases needing surgery to reconstruct the intestine, the researchers said. The resulting healthcare costs total over $3 billion each year. Despite better small bowel obstruction outcomes overall, post-surgery mortality increased from 4.4% to 5.9% after use of the dye became standard, and reoperations within 30 days rose from 4.7% to 6.2% - likely because surgeries were probably more complex in the later era, the researchers said. Gastrografin testing had weeded out patients with relatively mild obstructions who ultimately didn't need surgery, they added. 'Previously, patients who had a relatively mild adhesive small bowel obstruction would have been operated on, as we didn't have an alternative option,' study leader Dr. Robert McLoughlin from the University of Connecticut School of Medicine in Farmington said in a statement. 'This meant that in the post-Gastrografin era, the surgeries were more complex and challenging, hence the increased morbidity and mortality.' Still, because surgeons have gotten better at managing patients after surgery for small bowel obstructions, patients in the Gastrografin group averaged 6 days in the hospital, versus about 10 days for patients treated before the Gastrografin era, the researchers reported in the Journal of Surgical Research, opens new tab. The current study was not designed to prove that any of the outcomes were the result of Gastrografin use, the article pointed out. McLoughlin recalled that during a discussion with a younger colleague about managing small bowel obstructions, he mentioned that when he was in training, surgeons operated 'on a lot more' of these patients. That recollection prompted the current study, he said. (To receive the full newsletter in your inbox for free sign up here)
